Chapter 7. Genetic Targeting of Adenoviral Vectors

  1. David T. Curiel M.D. and
  2. Joanne T. Douglas Ph.D.
  1. Thomas J. Wickham Ph.D.

Published Online: 31 MAR 2003

DOI: 10.1002/0471234303.ch7

Vector Targeting for Therapeutic Gene Delivery

Vector Targeting for Therapeutic Gene Delivery

How to Cite

Wickham, T. J. (2002) Genetic Targeting of Adenoviral Vectors, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch7

Editor Information

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Author Information

  1. GenVec, Inc., Gaithersburg, Maryland, USA

Publication History

  1. Published Online: 31 MAR 2003
  2. Published Print: 9 AUG 2002

ISBN Information

Print ISBN: 9780471434795

Online ISBN: 9780471234302



  • adenovirus;
  • targeting;
  • receptor;
  • CAR;
  • integrins;
  • fiber;
  • penton base;
  • cancer;
  • ligand;
  • peptides


Multiple clinical protocols using adenovirus vectors are currently entering pivotal clinical trials. Despite these successes, the lack of tissue specificity of first generation adenovirus vectors has restricted their use for certain applications. This review will focus on advances and future directions for increasing the efficiency and specificity of adenovectors. Based upon recent advances it is highly likely that truly targeted adenovirus vectors will soon be developed for clinical application. This achievement will open up a whole new era in adenovirus gene therapy where the vector is selectively designed for the disease indication.